EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Platform-agnostic quantification for molecular interception of oral and esophageal malignancies: a global study addressing the diagnostic divide

Hung-Ming Lai iD, Hua-Ping Liu, Kaia Douglas, Keith Johnson, Xuanhua P Xie iD

JNCI Cancer Spectrum · 02.11.2026 · 10 (6)

DOI: 10.1093/jncics/pkag102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 05.10.2026. Verfasst von Hung-Ming Lai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, United States. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Mouth Neoplasms, Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH, COBRE Pilot.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral squamous cell carcinoma (OSCC) and esophageal squamous cell carcinoma are commonly diagnosed late because histopathology is subjective and robust molecular tools are lacking. Using interpretable machine learning, we aimed to develop an objective and platform-agnostic molecular measure of malignancy that could overcome the technical and geographic barriers associated with conventional genomic testing.

Methods

Using a discovery-to-generalization framework with 2541 samples, we developed and validated a single-sample transcriptomic scoring system called EsoralPrint. We feature-engineered 34 intrasample ordinal gene pairs (isoPairs) that capture consistent expression-order reversals between malignant and healthy states. The system was trained on oral tissues and externally validated across diverse global cohorts spanning the upper aerodigestive tract, technical platforms, and geographic regions. Independent single-cell RNA sequencing was used to provide post hoc mechanistic explainability.

Results

In the discovery cohort, EsoralPrint distinguished patients histologically graded as having low-risk hyperplasia who nonetheless progressed to cancer (log rank P < .001); we treated this result as exploratory pending independent confirmation. In external validations, EsoralPrint reached 95.0% accuracy and a 96.7% F1 score across OSCC cohorts (460 OSCC, 162 non-OSCC) and 91.6% accuracy and a 91.6% F1 score in esophageal tissue unseen during discovery and training (574 esophageal squamous cell carcinoma, 614 healthy mucosa samples). Further, a malignancy gradient reflecting field cancerization effects in resection boundaries was observed, and a transition zone (scores 0.25-0.75) was defined where molecular alterations preceded morphological changes.

Conclusion

EsoralPrint provides a platform-independent and quantitative complement to histological grading in oral and esophageal squamous malignancy, with the potential to give clinicians lead time for intervention. The tool can be accessed at https://github.com/aiphaqua/EsoralPrint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsMouth NeoplasmsEsophageal Squamous Cell CarcinomaCarcinoma, Squamous CellTranscriptomeGene Expression ProfilingHumansMachine LearningHyperplasiaSingle-Cell Gene Expression AnalysisFemale

Autor:innen und Institutionen

  • Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, United States.
  • Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States.
  • Aiphaqua Clinomics, Taipei, Taiwan.
  • Department of Oral Biology, College of Dentistry, University of Nebraska Medical Center, Omaha, NE, United States.

ORCID-Profile: Hung-Ming Lai, Xuanhua P Xie

Förderung

  • NIGMS NIH HHS
  • NIH
  • COBRE Pilot
  • NCI NIH HHS
  • Fred & Pamela Buffett Cancer Center Support
  • DHHS
  • National Cancer Institute
  • NIGMS

Zitieren

APA

Lai, H. M., Liu, H. P., Douglas, K., Johnson, K., & Xie, X. P. (2026). Platform-agnostic quantification for molecular interception of oral and esophageal malignancies: a global study addressing the diagnostic divide. JNCI Cancer Spectrum, 10(6). https://doi.org/10.1093/jncics/pkag102

Vancouver

Lai HM, Liu HP, Douglas K, Johnson K, Xie XP. Platform-agnostic quantification for molecular interception of oral and esophageal malignancies: a global study addressing the diagnostic divide. JNCI Cancer Spectrum. 2026;10(6). doi:10.1093/jncics/pkag102

BibTeX
@article{Lai2026,
  author = {Lai, Hung-Ming and Liu, Hua-Ping and Douglas, Kaia and Johnson, Keith and Xie, Xuanhua P},
  title = {Platform-agnostic quantification for molecular interception of oral and esophageal malignancies: a global study addressing the diagnostic divide},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {6},
  doi = {10.1093/jncics/pkag102}
}
Kostenlos starten →